Recombinant Pig Protein Asterix (WDR83OS)

What is Pig Protein Asterix (WDR83OS) and what cellular functions does it perform?

Asterix, encoded by the WDR83OS gene, is a 106-amino acid protein that functions as part of the PAT (protein associated with ER translocon) complex by heterodimerizing with CCDC47. This complex serves as a chaperone for large proteins containing transmembrane domains (TMDs), ensuring proper folding during membrane insertion .

The protein contains three transmembrane domains with the N-terminus facing the cytosol and C-terminus oriented toward the ER lumen. These TMDs are unusually short (approximately 15 amino acids each) and contain numerous hydrophilic residues and multiple cysteines that facilitate interaction with client proteins .

Methodology for functional analysis typically involves crosslinking experiments combined with mass spectrometry to identify interaction partners and characterize the chaperone activity in various cellular contexts.

How should recombinant WDR83OS protein be handled for optimal experimental results?

For optimal experimental results with recombinant WDR83OS, follow these methodological guidelines:

• Storage: Store at -20°C/-80°C upon receipt. Aliquoting is necessary for multiple use to avoid repeated freeze-thaw cycles which can compromise protein integrity .

• Reconstitution protocol:

  • Briefly centrifuge the vial prior to opening

  • Reconstitute in deionized sterile water to 0.1-1.0 mg/mL

  • Add 5-50% glycerol (final concentration) for long-term storage

  • Typical storage buffer consists of Tris/PBS-based buffer with 6% Trehalose at pH 8.0

• Quality control: Verify protein purity (>90% as determined by SDS-PAGE) and functional integrity through binding assays or structural studies before experimental use .

What experimental evidence supports Asterix's role in membrane protein biogenesis?

Multiple experimental approaches have established Asterix's role in membrane protein biogenesis:

• Crosslinking studies: Site-specific photo-crosslinking experiments have shown that Asterix directly engages TMDs that expose hydrophilic residues within the lipid bilayer, in a position-independent manner .

• Substrate preference analysis: Replacement of polar amino acids in TMDs with leucine markedly reduces Asterix-TMD interaction, while reintroduction of polar or charged residues partially restores this interaction, demonstrating specificity for TMDs with exposed hydrophilic residues .

• Native immunoprecipitation: Analysis via CCDC47 native IPs confirms that Asterix can crosslink with TMDs of either orientation and different unrelated sequences .

• Loss-of-function studies: Depletion of PAT complex components leads to impaired membrane protein biogenesis, indicating their requirement for optimal folding of multi-spanning membrane proteins .

How does the molecular mechanism of WDR83OS/Asterix differ from other membrane protein chaperones?

The molecular mechanism of WDR83OS/Asterix represents a distinct chaperoning strategy compared to other membrane protein chaperones:

• Substrate recognition specificity: Unlike many chaperones that recognize hydrophobic patches, Asterix preferentially engages TMDs with exposed hydrophilic residues within the lipid bilayer. This is analogous to how soluble chaperones prefer hydrophobic patches exposed to the aqueous environment, but with an inverted recognition paradigm .

• Substrate release mechanism: The PAT complex appears to be displaced by the more favorable TMD-TMD interactions that accompany correct folding. This substrate-driven displacement mechanism differs from ATP-dependent release mechanisms seen in many other chaperone systems .

• Intramembrane chaperoning: The PAT complex functions as an intramembrane chaperone, directly interacting with TMDs within the lipid bilayer. This distinguishes it from cytosolic or lumenal chaperones that typically engage extramembrane domains .

Methodologically, comparative analysis between WDR83OS and other chaperones requires techniques like hydrogen-deuterium exchange mass spectrometry, site-directed mutagenesis, and in vitro reconstitution with purified components to map binding interfaces and functional domains.

What is the relationship between WDR83OS mutations and neurodevelopmental disorders?

Research has established significant connections between WDR83OS mutations and neurodevelopmental disorders:

• Clinical phenotype: Biallelic variants in WDR83OS, particularly homozygous truncating variants, are associated with neurodevelopmental disorders characterized by facial dysmorphism (13/14 patients), intractable itching (9/14), and elevated bile acids (5/6 tested), with normal to mildly elevated liver enzymes .

• Developmental trajectory: In some affected individuals, a progressive reduction in relative head circumference has been observed over time, suggesting ongoing developmental impact .

• Animal model evidence: A zebrafish model lacking Wdr83os function supports its crucial role in the nervous system, craniofacial development, and lipid absorption, recapitulating key aspects of the human phenotype .

• Molecular mechanism: The disease mechanism appears to involve biallelic loss-of-function of WDR83OS leading to neurological disease with hypercholanemia. This mechanism is conceptually similar to that described for biallelic CCDC47 variants, which cause trichohepatoneurodevelopmental syndrome .

Methodologically, researchers investigating this relationship typically employ family-based rare variant analyses of exome sequencing data, case matching through platforms like GeneMatcher, and functional validation in animal models.

What techniques are most effective for studying WDR83OS interactions with other components of the PAT complex?

To effectively study WDR83OS interactions with other PAT complex components, particularly CCDC47, researchers can employ these advanced methodological approaches:

• Crosslinking-mass spectrometry (XL-MS): This approach can capture transient interactions and map precise contact sites between Asterix and its binding partners.

• Proximity labeling: BioID or APEX2 fused to WDR83OS can identify proteins in close proximity under native cellular conditions.

• Reconstitution systems: Purified components can be reconstituted in liposomes or nanodiscs to study interactions in a controlled membrane environment.

• Co-immunoprecipitation under non-denaturing conditions: This approach has successfully identified six proteins enriched more than 2-fold relative to controls, including Sec61α and Sec61β, the lectins Calnexin and Galectin-7, signal peptide peptidase (SPP), and CCDC47 .

• Site-specific photo-crosslinking: This technique has been optimized to map interactions between Asterix and transmembrane domains at specific sites and can reveal dynamic changes in these interactions .

How can researchers optimize expression and purification of functional recombinant WDR83OS?

Optimizing expression and purification of functional recombinant WDR83OS requires addressing several technical challenges:

• Expression system selection:

  • Prokaryotic systems (E. coli) have been successfully used to express full-length pig Asterix protein with N-terminal His tags

  • For functional studies, mammalian or insect cell expression systems may better preserve native folding and post-translational modifications

• Purification strategy:

  • Metal affinity chromatography using His-tags has proven effective for initial purification

  • Consider size exclusion chromatography as a second purification step to ensure removal of aggregates

  • When using denaturing conditions, implement controlled refolding through dialysis against decreasing concentrations of denaturant

• Protein folding verification:

  • Circular dichroism spectroscopy to assess secondary structure content

  • Tryptophan fluorescence to monitor tertiary structure

  • Functional binding assays to confirm biological activity

• Stability optimization:

  • Addition of 6% trehalose to storage buffer enhances stability

  • Aliquoting and storing at -80°C prevents repeated freeze-thaw cycles

  • Consider addition of mild detergents for membrane protein stability

What experimental approaches can identify the complete spectrum of WDR83OS client proteins?

To comprehensively identify WDR83OS client proteins, researchers should implement a multi-faceted experimental strategy:

• Proximity-dependent biotinylation:

  • Express BioID or APEX2 fused to WDR83OS in various cell types

  • Purify biotinylated proteins and identify by mass spectrometry

  • Validate hits through co-immunoprecipitation and functional assays

• Crosslinking approaches:

  • Utilize photo-activatable or chemical crosslinkers to capture transient interactions

  • Optimize crosslinking conditions to preferentially capture client proteins during folding

  • Use mass spectrometry to identify crosslinked partners

• Comparative proteomics:

  • Compare membrane protein composition and folding efficiency in wild-type versus WDR83OS-depleted cells

  • Focus analysis on multi-pass membrane proteins with hydrophilic residues in TMDs

  • Quantify changes in protein levels, membrane integration, and aggregation

• Pulse-chase experiments:

  • Monitor the fate of newly synthesized membrane proteins in the presence or absence of WDR83OS

  • Identify proteins whose maturation is delayed or compromised when WDR83OS is depleted

  • Focus on proteins that interact with PAT complex during early stages of biogenesis

How do disease-associated variants in WDR83OS affect its molecular function?

Analysis of disease-associated variants in WDR83OS reveals several impacted molecular pathways:

• Protein structure alterations:

  • Homozygous truncating variants likely result in complete loss of function

  • Missense variants may disrupt specific functional domains, particularly the TMDs that engage client proteins

  • Structural modeling can predict how specific variants affect protein folding or interaction interfaces

• Disrupted cellular pathways:

  • Neurodevelopmental effects suggest impaired folding of critical neuronal membrane proteins

  • Elevated bile acids (hypercholanemia) in patients indicates disruption of cholesterol/bile acid metabolism

  • Intractable itching suggests potential dysregulation of sensory receptors or inflammatory pathways

• Experimental approaches for variant characterization:

  • Generate cellular models expressing disease variants using CRISPR/Cas9

  • Assess chaperone activity of wild-type versus mutant WDR83OS using misfolding-prone reporter proteins

  • Perform transcriptomic and proteomic analyses to identify dysregulated pathways

  • Use zebrafish models to correlate molecular defects with developmental outcomes